The IPPF is excited to announce that Ellen Levine,...
The Sy Syms Foundation has awarded a $100,000 grant...
Genentech announced this week that positive top line results...
As a NORD IAMRARE™ Registry Partner, the IPPF is...
On April 23, 2019, Akari Therapeutics, Plc (Nasdaq: AKTX),...
On March 15, 2019, Roche announced that the European...
On March 2, 2019, Principia Biopharma Inc. (Nasdaq: PRNB), a...
On February 22, 2019, Principia Biopharma Inc. (Nasdaq: PRNB),...
2018 was an exciting year for the IPPF!
Our laboratory researches a rare and debilitating autoantibody-mediated disease...
On September 12, 2018, the U.S. Food and Drug...
The 2018 IPPF Patient Education Conference was an amazing...
Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company...
Transformative Research Award Will Support Further Pemphigus Research Nicola...
The U.S. Food and Drug Administration (FDA) has granted...
The Sy Syms Foundation has awarded a $75,000 grant...
The U.S. Food and Drug Administration (FDA) has granted...
Pemphigus and pemphigoid (P/P) patients may agree that in...
On Thursday, June 7th, the FDA approved Rituxan for...
Syntimmune recently announced positive preliminary results from its phase...
